65,437 trials
Acromegaly
Primary: Responder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 13 — 66.7; 25.0; 16.7 percentage of responders
Gestational Diabetes
Primary: Primary Composite Outcome — 150; 167 Participants — p=0.13
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib — 176; 174; 180 nanograms per milliliter (ng/mL)
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib — 1520; 1350 nanograms per milliliter (ng/mL)
Microbial Colonization
Primary: Phylum Level Mean Proportional Relative Abundance — 0.167; 0.0271; 0.686; 0.0391 % gram positive (+) for phylum
Opioid Use
Primary: MOUD Retention Rate — .42 number of days missed MOUD appointment
Drug-Drug Interaction · HIV Infection
Primary: AUC0-42day in 3-dose Study — 4.47; 14.9; 49.7; 14.6 hr.ug/mL
Breast Cancer · Metastatic Breast Cancer · BRCA1 Gene Mutation
Primary: Objective Response Rate (ORR) of ABT-888 and Temozolomide (TMZ) in Metastatic Breast Cancer — 4; 3 Participants
Asthma and/or Exercise Induced Bronchoconstriction · Ozone Air Pollution
Primary: Measured Before and 30 Minutes After Exercise in Each 1 Day Condition — 6.98; 5.96; -1.38; -.35 litres
Squamous Cell Carcinoma of the Head and Neck · Melanoma · Non Small Cell Lung Cancer
Primary: Safety Profile of SL-279252 — 1; 1; 2; 1 Participants
Behavioral Health
Primary: Change in Monetary Choice Questionnaire — -3.86; -4.13; -4.33 score on a scale — p=.191
Behavioral Health
Primary: Change in Delay Discounting 5 Trial Adjusted Measure — -3.87; -5.03 log (k) — p=.124
Histoplasmosis · AIDS
Primary: Clinical Response — 32; 25; 28 Participants
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
HIV Infection · Vaginal Atrophy · Menopause
Primary: Change in Most Bothersome Symptom (MBS) of Vaginal Atrophy — 0; 1; 8; 4 Participants